Scientific investigation into BPC-157 and TB-500 remains ongoing, with much of the current interest based on preclinical studies, mechanistic research and anecdotal usage reports from peptide communities
In the NEJM Phase 2 trial, participants assigned to an initial dose of 4 mg experienced significantly more adverse events than those who started at 2 mg, even when both groups ultimately reached the same target dose
GLP-1 analogs are often evaluated alongside GIP, glucagon, or amylin activity depending on the product family and experimental design
Compounders Question FDAs Rationale and Evidence Pointing to Safety Concerns On October 27, 2023, APC urged FDA via letter addressed to Gail Bormel, Director of the FDA's Office of Compounding Quality and Compliance, for transparency regarding the recent inclusion of substances into Category 2
Singh AK, Liu Y, Riederer B, et al
Drug Interactions: Inform your healthcare provider about all medications and supplements you are taking